Is RYTM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Acquired hypothalamic obesity launch, with revenue (ttm) at ~$220M. The bear case rests on rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. Analysts covering it are spread from $105.00 to $155.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $105.00, -1.9% from the $107.01 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Acquired hypothalamic obesity launch. The FDA approved IMCIVREE for acquired hypothalamic obesity in March 2026, and Rhythm reported more than 150 patient start forms within the first six weeks. The most optimistic analyst target on RYTM is $155.00, +44.8% from the $107.01 price. That figure is only reachable if this thesis works close to its best case.

Rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company. It is not yet profitable and posts substantial quarterly net losses (around $56 million in the first quarter of 2026), so it relies on its cash balance (about $341 million as of the first quarter of 2026) and potential future financing. The valuation, with a market cap near $8 billion against roughly $220 million in trailing revenue, prices in aggressive future growth that may not materialize. Clinical trials such as the bivamelagon Phase 3 can fail, and the broader obesity market is dominated by far larger GLP-1 players like Novo Nordisk and Eli Lilly whose drugs could encroach on parts of Rhythm's niche. The most pessimistic published target is $105.00, -1.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Rhythm Pharmaceuticals is a Boston-based biopharmaceutical company focused on rare diseases of obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway, the brain ci

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Acquired hypothalamic obesity launch) stalling in the reported numbers rather than in the narrative, the risk above (rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Rhythm develops treatments for rare diseases of obesity driven by the brain's MC4R pathway. Its marketed drug, IMCIVREE (setmelanotide), is approved for certain rare genetic obesity disorders, Bardet-Biedl syndrome, and, as of March 2026, acquired hypothalamic obesity.

No. As of July 2026 Rhythm is still unprofitable, reporting a net loss of roughly $55.6 million in the first quarter of 2026 as it spends heavily on its product launch and pipeline. It funds operations from its cash balance of about $341 million.

IMCIVREE produced about $60.1 million in net product revenue in the first quarter of 2026, up modestly from the prior quarter, for roughly $220 million on a trailing-twelve-month basis. Revenue is split between the U.S. and international markets.